Life Sciences Tools and Services
Company Overview of Aphios Corporation
Aphios Corporation develops enabling biotechnology and nanotechnology drug delivery platforms. It also manufactures quality-of-life medicines for health maintenance; research chemicals for standards; and active pharmaceutical ingredients for pharmaceuticals. The company’s therapeutic products include Zindol, an enhanced ginger product; APH-0703, a potent protein kinase C (PKC) activator; APH-0812, a combination therapy consisting of PKC modulators with or without HDAC inhibitors; AMPI-109, a nontoxic Vitamin D3 derivative for hormone refractory prostate cancer; APH-0911, a nanotechnology formulation of Taxotere prodrug with sugar side chain that improves the oral bioavailability of water-sol...
3-E Gill Street
New Boston Park
Woburn, MA 01801
Founded in 1993
Key Executives for Aphios Corporation
Founder, Chairman of The Board, Chief Executive Officer and President
Compensation as of Fiscal Year 2015.
Aphios Corporation Key Developments
Aphios Completes Enrollment in Phase I/II Clinical Trial Towards an HIV Cure
Jun 2 15
Aphios Corporation announced that clinical trial enrollment has been completed for a Phase I/II clinical trial on APH-0812 for HIV latency in Madrid, Spain. Aphios is collaborating with researchers at the University of Córdoba, Córdoba, Spain and clinical investigators led by Dr. Santiago Moreno at the Department of Infectious Diseases, Ramón y Cajal Hospital, Madrid, Spain to conduct a Phase I/II randomized, placebo-controlled clinical trial initially on the PKC component (Bryostatin-1) of APH-0812 in cART-treated HIV patients in Spain.
Aphios Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Jan 10 15
Aphios Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries